SV2012004203A - Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen - Google Patents

Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen

Info

Publication number
SV2012004203A
SV2012004203A SV2012004203A SV2012004203A SV2012004203A SV 2012004203 A SV2012004203 A SV 2012004203A SV 2012004203 A SV2012004203 A SV 2012004203A SV 2012004203 A SV2012004203 A SV 2012004203A SV 2012004203 A SV2012004203 A SV 2012004203A
Authority
SV
El Salvador
Prior art keywords
hexahydrociclopenta
acetilcolinesterase
propoxi
pirrol
cis
Prior art date
Application number
SV2012004203A
Other languages
English (en)
Inventor
Caryn Trocme-Thibierge
Aurore Sors
Florence Keime-Guibert
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44351420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2012004203(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of SV2012004203A publication Critical patent/SV2012004203A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ASOCIACIÓN ENTRE LA 4-{3-[CIS-HEXAHIDROCICLOPENTA[C]PIRROL-2(1H)-IL]PROPOXI}BENZAMIDA DE FÓRMULA (I): (VER FORMULA); O UNA DE SUS SALES DE ADICIÓN A UN ÁCIDO O A UNA BASE FARMACÉUTICAMENTE ACEPTABLE Y UN INHIBIDOR DE LA ACETILCOLINESTERASA
SV2012004203A 2011-05-02 2012-05-02 Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen SV2012004203A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1101347A FR2974729B1 (fr) 2011-05-02 2011-05-02 Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
SV2012004203A true SV2012004203A (es) 2012-08-23

Family

ID=44351420

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2012004203A SV2012004203A (es) 2011-05-02 2012-05-02 Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen

Country Status (28)

Country Link
US (3) US8940785B2 (es)
EP (1) EP2520296A1 (es)
JP (1) JP2012232978A (es)
KR (2) KR101493757B1 (es)
CN (1) CN102764439A (es)
AP (1) AP3104A (es)
AR (1) AR086146A1 (es)
BR (1) BR102012010244A2 (es)
CA (1) CA2775624A1 (es)
CL (1) CL2012001102A1 (es)
CR (1) CR20120192A (es)
CU (1) CU20120064A7 (es)
EA (1) EA020987B1 (es)
EC (1) ECSP12011862A (es)
FR (1) FR2974729B1 (es)
GE (1) GEP20146076B (es)
MA (1) MA34776B1 (es)
MX (1) MX2012005103A (es)
NI (1) NI201200070A (es)
PE (1) PE20130016A1 (es)
RU (1) RU2013153140A (es)
SG (2) SG185240A1 (es)
SV (1) SV2012004203A (es)
TN (1) TN2012000177A1 (es)
TW (1) TW201247200A (es)
UY (1) UY34050A (es)
WO (1) WO2012150412A1 (es)
ZA (1) ZA201203163B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2976285B1 (fr) * 2011-06-08 2013-05-24 Servier Lab Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent
ME03812B (me) 2016-08-18 2021-04-20 Suven Life Sciences Ltd Kombinacija inverznih agonista histamin-3 receptora sa inhibitorima acetilholinesteraze
JP6734469B2 (ja) * 2016-08-18 2020-08-05 スヴェン・ライフ・サイエンシーズ・リミテッドＳｕｖｅｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｉｍｉｔｅｄ ヒスタミン−３受容体インバースアゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種組合せ
CN108371660B (zh) * 2017-12-14 2020-03-10 五邑大学 一种四氢环戊二烯并吡咯化合物及其衍生物的用途
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
EP3973586A4 (en) * 2019-05-21 2023-01-11 La Pharma Tech Inc. NEW PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL, BEHAVIORAL AND COGNITIVE DISORDERS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RS50756B (sr) * 2004-04-28 2010-08-31 Takeda Pharmaceutical Company Limited Fuzionisani derivati hinolina i njegova upotreba
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
TW200845977A (en) * 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
AR068764A1 (es) * 2007-10-10 2009-12-02 Takeda Pharmaceutical N-piperazin amidas y su uso en medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de faah.
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
FR2937251B1 (fr) * 2008-10-16 2011-03-18 Servier Lab Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
FR2953515B1 (fr) * 2009-12-09 2011-12-23 Servier Lab Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
ECSP12011862A (es) 2012-07-31
CU20120064A7 (es) 2013-12-27
GEP20146076B (en) 2014-04-10
MX2012005103A (es) 2013-06-05
AP3104A (en) 2015-01-31
AP2012006232A0 (en) 2012-04-30
EA020987B1 (ru) 2015-03-31
FR2974729B1 (fr) 2013-04-19
KR101493757B1 (ko) 2015-02-16
US8940785B2 (en) 2015-01-27
ZA201203163B (en) 2013-01-30
UY34050A (es) 2012-11-30
EP2520296A1 (fr) 2012-11-07
BR102012010244A2 (pt) 2013-06-18
US20150080379A1 (en) 2015-03-19
EA201200527A1 (ru) 2012-12-28
KR20140051200A (ko) 2014-04-30
CR20120192A (es) 2012-12-06
RU2013153140A (ru) 2015-06-10
NI201200070A (es) 2012-11-09
US20120283244A1 (en) 2012-11-08
US20150080378A1 (en) 2015-03-19
MA34776B1 (fr) 2014-01-02
PE20130016A1 (es) 2013-01-26
KR20130130238A (ko) 2013-12-02
SG185240A1 (en) 2012-11-29
CL2012001102A1 (es) 2014-06-20
WO2012150412A1 (fr) 2012-11-08
JP2012232978A (ja) 2012-11-29
SG2014010904A (en) 2014-05-29
FR2974729A1 (fr) 2012-11-09
CN102764439A (zh) 2012-11-07
NZ599633A (en) 2014-02-28
CA2775624A1 (fr) 2012-11-02
TN2012000177A1 (fr) 2013-12-12
TW201247200A (en) 2012-12-01
AR086146A1 (es) 2013-11-20

Similar Documents

Publication Publication Date Title
SV2012004203A (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
DOP2014000016A (es) Indazoles novedosos inhibidores de janus quinasa
CO7160104A2 (es) Inhibidores de virus de hepatitis c
HN2011003072A (es) Sales de disacarina, ácido difumárico, ácido d1-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(demitilamino)butilo
UA108240C2 (uk) Похідні гексафторізопропілкарбамату, їх одержання і їх терапевтичне застосування
CR20120526A (es) Proceso para la preparación de 4-{4[({[4-cloro-3-(trifluorometilo)-fenilo] amino} carbonilo) amino]-3-fluorofenoxi}-n-metilpiridino-2-carboxamida, sus sales y monohidrato
UY33226A (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
CR20140134A (es) Composiciones farmacéuticas
CO6950494A2 (es) Composiciones de herbicida-protector que contienen amidas de ácido n-(tetrazol-5-il)-carbónico y n-(triazol-5-il9arilcarbónico
DK3489226T3 (da) Hæmmere for natriumglucose-cotransporter 1
CR20140294A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CR20140494A (es) Inhibidores de dgat1 de eter ciclico de cabeza de puente
CR20140133A (es) Compuestos de piridazinona y sus usos como inhibidores de daao
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
SV2012004235A (es) Nuevos co-cristales de agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20140462A (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil} amino) -1-hidroxietil]-8-hidroquinolin-2(1h)-ona
CO6660080A1 (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen
CY1116739T1 (el) Μεθοδος συνθεσης και κρυσταλλικη μορφη του υδροχλωρικου 4-{3-[cis-εξαϋδροκυκλοπεντα[c]πυρρολ-2(1η)-υλ] προποξυ} βενζαμιδιου καθως και η συνδεομενη ελευθερη βαση και οι φαρμακευτικες συνθεσεις οι οποιες τις περιεχουν
AR080127A1 (es) Inhibidores de la amida hidrolasa de acidos grasos, composiciones farmaceuticas y sus usos
ES2530436T3 (es) Combinación
UY35108A (es) Nuevo procedimiento de síntesis del (2e)-3-(3,4-dimetoxifenil) prop-2-enonitrilo, y aplicación a la síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
UY34423A (es) Nuevo procedimiento de síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
UA112407C2 (uk) Співкристали агомелатіну, спосіб їх виготовлення і фармацевтичні композиції, що їх містять
NI201500087A (es) Formulación farmacéutica de n-[5-[2-(3-,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r, 5s)-3, 5 - dimetl piperazin - 1 il] benzamida